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Objective: Genetic disorders of calcium metabolism arise in a familial or sporadic setting. The calcium-
sensing receptor (CASR) plays a key role in maintaining calcium homeostasis and study of the CASR
gene can be clinically useful in determining etiology and appropriate therapeutic approaches. We
report two cases of novel CASR gene mutations that illustrate the varying clinical presentations and
discuss these in terms of the current understanding of CASR function.
Patients and methods: A 16-year-old patient had mild hypercalcemia associated with low-normal
urinary calcium excretion and normal-to-high parathyroid hormone (PTH) levels. Because of negative
family history, familial hypocalciuric hypercalcemia was originally excluded. The second patient was a
54-year-old man with symptomatic hypocalcemia, hyperphosphatemia, low PTH, and mild
hypercalciuria. Familial investigation revealed the same phenotype in the patient’s sister. The coding
region of the CASR gene was sequenced in both probands and their available first-degree relatives.
Results: The first patient had a novel heterozygous inactivating CASR mutation in exon 4, which
predicted a p.A423K change; genetic analysis was negative in the parents. The second patient had a
novel heterozygous activating CASR mutation in exon 6, which predicted a p.E556K change; the
affected sister of the proband was also positive.
Conclusions: We reported two novel heterozygous mutations of the CASR gene, an inactivating mutation
in exon 4 and the first activating mutation reported to date in exon 6. These cases illustrate the
importance of genetic testing ofCASR gene to aid correct diagnosis and to assist in clinical management.
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Extracellular ionized calcium (Ca2C) values are main-
tained within a very narrow range as a result of a
complex homeostatic system that regulates cell signal-
ing, bone metabolism, neural and muscle function.
Parathyroid hormone (PTH) plays the key role in
modulating ionized levels via its actions on renal
tubular cells and bone resorption, while it is also crucial
for intestinal absorption of calcium through its
regulation of enzymatic activation of vitamin D (1–3).
PTH synthesis and secretion is finely regulated by the
calcium-sensing receptor (CASR) on parathyroid gland
cells. The CASR senses minor fluctuations in ionized
calcium levels and can rapidly modulate PTH appro-
priately to maintain optimal circulating Ca2C (4, 5).
Inborn disorders of calcium metabolism causing hypo-
and hyper-calcemia have multiple etiologies. Hypopar-
athyroidism occurs in the setting of several congenital
syndromes such as Di George, Kenny-Caffey, and Barakatndocrinologysyndromes or as part of polyglandular autoimmune
disorders (6); there are also isolated, sporadic or familial
genetic diseases. Familial forms of hypoparathyroidism
can be related to mutations of the PTH gene (7, 8), the
CASR gene (9), and the ‘glial cells missing’ gene (10),
with a X-linked form of the disease also being described
(11). Genetic conditions related to hyperparathyroidism
include multiple endocrine neoplasia types 1 (MEN1) and
2 (MEN2), familial hypocalciuric hypercalcemia (FHH),
hyperparathyroidism-jaw tumor syndrome and familial
isolated hyperparathyroidism (12).
Mutations in the CASR gene may cause hypo- or
hypercalcemia. The CASR belongs to the subfamily C of
the G protein-coupled receptors (13) and is organized in
three major structural domains: a large amino-terminal
extracellular domain (ECD), the typical seven trans-
membrane domains (TMD), and a cytoplasmic carboxy-
terminal tail (14). The Venus flytrap (VFT) model has
been proposed to illustrate the CASR–ligand interaction
(15), showing two possible conformations: an openDOI: 10.1530/EJE-11-0121





































Figure 1 Clinical case 1. Changes in serum calcium (Ca) and PTH
during oral calcium-loading test: the increase in Ca levels from 2.95
to 3.23 mmol/l was associated with a 40% PTH suppression,
supporting a possible diagnosis of primary hyperparathyroidism.
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a low-affinity pocket in the ECD and a closed confor-
mational status in which the ligand binds a second
high-affinity domain. The bound N-terminal segment
interacts with the membrane-associated domain to
generate a signal. Molecular studies indicated that
calcium interacts with polar residues in the binding
pockets in the ECD of the receptor, emphasizing the role
of eight residues (Ser 147, Ser 170, Asp 190, Gln 193,
Tyr 218, Phe 270, Ser 296, and Glu 297) in calcium
coordination (15, 16).
The human CASR gene is located on chromosome 3
(17) and contains six coding exons (18), from exons 2 to
7. The amino-terminal ECD is encoded by the exons 2–6
and the beginning of exon 7, while the TMD and the
cytoplasmic tail are encoded by exon 7.
Over the past decade around 150 inactivating
mutations and 70 activating mutations have been
described. Inactivating mutations have been described
in the context of FHH and neonatal severe primary
hyperparathyroidism (NSHPT). Conversely, activating
mutations have been related to autosomal dominant
hypocalcemia (ADH) and type V Bartter syndrome.
This study describes two clinical cases of disordered
calcium homeostasis caused by novel CASR mutations
in the context of current understanding of the role of the
CASR in calcium homeostasis and disease.Patients and methods
Case 1
A 16-year-old patient (Table 1) was referred to the
University Hospital of Lie`ge for investigation of hypercal-
cemia noted during a routinely biochemical evaluation
for abdominal pain. Repeated calcium measurements
confirmed moderate hypercalcemia (mean value:
2.96 mmol/l; normal range: 2.15–2.60). Hypercalcemia
was associated with low-normal phosphate levels,
normal vitamin D status (serum 25-hydroxyvitamin D:
37 ng/ml) and mildly elevated PTH. The 24 h urinary
calcium excretion (24 h CaUr) was high-normal and the







Mean repeated Ca (mmol/l) 2.96 2.61 2.15–2.60
Mean repeated Ca2C (mmol/l) 1.56 – 1.00–1.30
PO3K4 (mg/l) 25 25 23–47
PTH (pg/ml) 66 69 12–58
25-Hydroxyvitamin D (ng/ml) 37 39 O32
Creatinine (mg/l) 6.5 7.4 4.5–12.1
24 h CaUr (mmol/24 h) 7.86 – 2.50–8.00
CCR 0.02 – 1.00–2.60
Ca, serum calcium; Ca2C, ionized calcium; PO3K4 , phosphate; PTH,
parathyroid hormone; 24 h CaUr, 24 h urine calcium; CCR, calcium/creatinine
clearance ratio.
www.eje-online.orgrepeated measurement (0.009–0.02). As previously
reported (19), a CCR!0.01 has been suggested as a
cut off value in patients with FHH in the absence of other
factors that would lower urinary calcium excretion,
whereas a CCRO0.02 supports hyperparathyroidism.
Both ultrasound and scintigraphy revealed no parathyr-
oid gland abnormality. An oral calcium-loading test was
performed. PTH, calcium and creatinine were measured
1 h before and 1, 2, and 3 h after calcium load. The
increase in serum calcium levels from 2.95 at baseline to
3.23 mmol/l was associated with partial (40%) suppres-
sion of PTH (from 60 to 34 pg/ml, Fig. 1). These results
suggested that PTH secretion was not completely
autonomous, which possibly suggested primary hyper-
parathyroidism (20). Conversely, biochemical evaluation
of both parents showed no serum or urine abnormality.
On the basis of hypercalcemia and slightly elevated PTH
levels in the proband and normal serum calcium in his
parents, FHH was originally excluded and primary
hyperparathyroidism was suspected.
Taking into account the negative long-term outcome
of primary hyperparathyroidism (21–23) and the age of
the patient, a surgical exploration of the parathyroid
glands was recommended. This showed normal ana-
tomic position, with the superior glands being slightly
increased in size and the inferior ones being clearly
hyperplasic. The inferior glands were resected surgically
and histological analysis confirmed the diagnosis of
parathyroid hyperplasia.
Postoperatively, serum calcium levels were still
slightly increased with persisting inappropriately
elevated PTH (69 pg/ml) and normal serum
phosphorus. Due to the persistent biochemical abnorm-
alities, genetic analysis of the CASR gene was under-
taken in all family members.
Nucleotide sequencing from the proband identified a
novel mutation from GCA to AAA at codon 423 in exon
4 of the CASR, resulting in a conversion of alanine to
lysine. DNA extraction and sequencing in both parents
revealed no mutation in CASR gene, and as molecular
analysis using microsatellite markers (24) indicated
that the paternity was as stated, a diagnosis of a de novo
heterozygous CASR mutation was made.
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Mean repeated Ca (mmol/l) 1.96 2.15–2.60
Mean repeated Ca2C (mmol/l) 1.00 1.00–1.30
PO3K4 (mg/l) 40 23–47
PTH (pg/ml) !12 12–58
Creatinine (mg/l) 8.4 4.5–12.1
24 h CaUr (mmol/24 h) 6.24 2.50–8.00
CCR 0.013 1.00–2.60
Ca, serum calcium; Ca2C, ionized calcium; PO3K4 , phosphate; PTH,










Figure 2 Clinical case 2. Pedigree of the patient’s family. The arrow
shows index patient and the filled symbols indicated affected family
members with a heterozygous CASR gene mutation.
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A 54-year-old man had hypocalcemia associated with
low PTH. In the previous 6 months, he had received
supplemental calcium carbonate (1000 mg daily) and
cholecalciferol (25 000 IU weekly) with serum calcium
remaining below the normal range. One month before
presentation he suffered a first grand mal epileptic
seizure. Computed tomography of the brain revealed
calcification in the basal ganglia and in the frontal
cerebral cortex. Biochemical evaluation confirmed the
presence of hypocalcemia in three consecutive
determinations: 1.91, 1.96, and 1.68 mmol/l, with
mean ionized Ca2C being 1.0 mmol/l. Hypocalcemia
was accompanied by low PTH levels (!12 pg/ml),
normal serum 25-OH vitamin D and serum phosphorus
of 40 mg/l. The 24 h CaUr was within the normal range
and CCR was 0.013. The patient profile at study entry is
shown in Table 2. Renal ultrasound showed normal
renal parenchymal structure without signs of nephro-
calcinosis and/or nephrolithiasis.
The family history was positive for a similar clinical
picture in the patient’s sister, who had received oral
calcium and vitamin D supplementation for some years
without biochemical normalization of calcium. Labora-
tory analyses in the sister revealed a serum calcium of
1.95 mmol/l, a low PTH (1.0 pg/ml), and a high-
normal 24 h CaUr and CCR of 0.026. Kidney ultra-
sound did not reveal parenchymal abnormalities,
whereas the brain computerized tomography showed
calcification in the basal ganglia. The patient’s father
was deceased; his mother and his son had normal
serum and urine biochemical tests.
Given the clinical history and familial nature of the
condition, genetic analysis of the CASR was performed.
In the proband a novel heterozygous mutation from
GAG to AAG at codon 556 in exon 6 of the CASR gene,
was found which resulted in a change from glutamic
acid to lysine (E556K).
The mutation was also present in the affected sister,
while the asymptomatic mother and son of the proband
had normal CASR sequencing (Fig. 2).Assays
Calcium, phosphorus, and creatinine were measured by
automated laboratory methods. The urinary calcium
and creatinine measurements were done on 24 h urine
samples. CCR was calculated with the following
formula: (U(Ca)!P(Crea)/P(Ca)!U(Crea)), where U
stands for urine, P for plasma, Crea for creatinine, and
Ca for calcium. PTH was measured by the direct
immunochemiluminescent sandwich assay (Liaison,
DiaSorin, MN, USA). The sensitivity of the assay was
1 ng/l. The intra-assay coefficient of variation (CV) was
1.7–3.7% and the inter-assay CV was 2.6–5.9%.DNA sequencing
Both probands and first-degree relatives provided
the written informed consent for the genetic analysis,
and the local ethics committee authorized the study.
DNA was extracted from peripheral blood sample on
EDTA by standard phenol–chloroform method. DNA
sequencing procedure is detailed in the Supplemental
Material (see section on supplementary data given at
the end of this article).Discussion
This study first describes two novel heterozygous
mutations of the CASR gene, a two nucleotide
inactivating A423K mutation in codon 4 and the
activating E556K mutation in codon 6.
Over the past decade more than 220 mutations of the
CASR gene have been described. Inactivating mutations
are generally related to FHH and NSHPT. On the
other hand, activating mutations have been described
in the context of ADH and type V Bartter syndromewww.eje-online.org
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the last 6 years, about 36 CASR gene mutations have
been described (25–38), with 34 being inactivating and
two activating. Among them, most have been found in
exons 4 and 7.
Efforts have been done to clarify the impact of these
genetic alterations on receptor function. An in vitro
functional study of the mutated receptor showed ligand-
dependent changes in receptor affinity (26). Inactivat-
ing mutations led either to total loss of function and
inability to bind calcium or to a lack of expression at the
membrane (26). At molecular level this could be the
result of an abnormal glycosylation, crucial disulfide
bond formation, and agonist-induced dimer confor-
mational changes or altered G-protein coupling (27).
The majority of inactivating mutations are missense.
Whether such missense mutations are more closely
related to increased serum calcium levels than truncat-
ing mutations remains speculative (28, 39).
Almost all activating mutations affect loop 2 of the
VFT domain and TMD 5, 6, and 7 (26). Activating
mutations are thought to increase receptor sensitivity
by facilitating ligand-induced VFT closure or dimer
rotation. Recent research points out the importance of
TMD 6 helix motion in receptor activation (39, 40).
Particularly, the TMD A843E mutation leads to a
constitutive activation of the CASR, independent of
calcium levels and ECD structure, probably locking the
TMD in an active conformation (41). Moreover, the
activating E297D and the inactivating E297K
mutations have been described in codon 297,
suggesting its crucial role in ligand binding and receptor
activation (15, 18).
FHH was first described as a heritable disorder of
mineral metabolism (42), inducing asymptomatic
hypercalcemia associated with hypocalciuria (43) and
inappropriate PTH levels (44). The presence of a normal
PTH in these patients is a direct consequence of an
elevated set point for calcium-regulated PTH secretion
(45). FHH is a benign autosomal dominant disease and
affected individuals usually do not show complications
related to hypercalcemia (46). Thus, medical and/or
surgical treatments are generally not recommended. In
our first case, a 16-year-old patient had the clinical
phenotype of mild hypercalcemia associated with high
PTH levels and a high-normal 24 h calcium excretion
value. Basal biochemical investigation of both this
patient and his parents, followed by oral calcium
loading and imaging, could not settle a clear initial
diagnosis. The discovery of parathyroid hyperplasia but
with a negative outcome of surgery led us to perform
genetic analysis of the CASR gene. Study in both parents
was negative and the family relationship was confirmed,
which indicates that the A423K mutation likely
occurred de novo, making this kindred technically not
a FHH family. However, analysis was performed on
somatic cells and did not exclude the possibility of germ-
line mosaicism as previously reported in the case of anwww.eje-online.orgactivating CASR mutation (46). This clinical case
confirms that differential diagnosis of mild hypercalce-
mia associated with normal-to-high PTH can be difficult
and is still a challenge for endocrinologists. This is in
line with a previous study reporting that in 23% of
patients with undiagnosed mutations in the CASR gene,
surgical exploration of the neck was undertaken as part
of the diagnostic workup (26). Several reports in the
literature showed that atypical presentation of FHH is
not a rare finding. Hypercalcemia associated with
hypercalciuria, high PTH levels and even nephrolithia-
sis (10, 47–50) could suggest hyperparathyroidism.
Moreover, such patients are less likely to achieve
normocalcemia after parathyroid surgery (4), as in
our first clinical case.
In inactivating CASR mutations a clear genotype–
phenotype relation is lacking. The first described
mutation F881L, associated with atypical FHH-like
phenotype (50), is located in the region encoding the
C-terminal tail. Thereafter, Rus et al. (51) described two
novel mutations with atypical phenotype affecting
amino acids in the C-terminal tail: Q926R and
D1005N. Several other mutations (V268del-11X273,
E250K, T100I, L650P, V689M, and 1008delAAG) have
been associated with atypical presentations, including
severe hypercalcemia, hypercalciuria with or without
nephrolithiasis and/or nephrocalcinosis, kindreds with
affected members displaying either hypercalciuria or
hypocalciuria, and normal calcium levels after surgery
and pancreatitis (10, 49). Interestingly, R886P, close to
F881L, has been associated to a typical phenotype (10).
In the second clinical case, we have described a family
with autosomal dominant hypoparathyroidism due to a
novel activating missense mutation in the CASR: E556K
in exon 6. To the best of our knowledge this is the first
activating mutation found in exon 6, all previously
described mutations being inactivating. Codon 556 is
situated within the Cys-rich domain involved in the
signaling between the VFT domain and the TMD7. The
strong correlation between phenotype (symptomatic
hypocalcemia, low PTH and relative hypercalciuria) and
genotype supported that this mutation is pathogenic.
The patient presented, albeit at a relatively advanced
age for the clinical condition, with symptomatic
hypoparathyroidism that had caused an epileptic
seizure and was associated with brain calcification.
Importantly, the patient had not suffered renal sequelae,
which represents an important morbidity in hypopar-
athyroidism, particularly in patients with his genetic
etiology of autosomal dominant hypoparathyroidism.
Treatment in these cases is particularly challenging
compared with other hypoparathyroid patients, as the
enhanced sensitivity of the mutant CASR in the kidney
to activation by calcium promotes hypercalciuria,
which is worsened by therapeutic intake of calcium
and vitamin D to alleviate symptoms (52). Care must be
taken to not over treat with supplemental calcium,
vitamin D or vitamin D analogs/metabolites, as the aim
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handling, and a low-normal serum calcium is preferable
to achieve this end.
Our clinical cases clearly exemplify that all first-
degree relatives of patients with calcium disorders and
inappropriate PTH levels should have calcium levels
examined after a detailed family history is obtained.
DNA sequencing is becoming more affordable, can lead
to accurate diagnosis and should therefore be carried
out in members of PTH-related families with abnorm-
alities in serum and urine excretion calcium, also
including young patients and atypical cases.
In conclusion, we have described two novel mutations
of the CASR gene. A423K is the first inactivating
mutation described in exon 4 and E556K is the first
activating mutation described in exon 6. It is
noteworthy that CASR gene mutations can be associ-
ated with symptomatic hyper- or hypocalcemia or
atypical clinical presentation.Supplementary data
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